Pseudorabies virus infection induces IRF1-dependent PANoptosis to provoke the excessive release of HMGB1 and IL-1β Authors: Liangzheng Yu, Yue Chen, Zhenbang Zhu, Herman W. Favoreel, Xiangdong Li Published: 2026 ABSTRACT PANoptosis is a newly described type of cell death that can be triggered upon microbial infection, autoinflammatory diseases, and cytokine storms, and involves the coordinated activation of pyroptosis, apoptosis, and necroptosis. Pseudorabies virus (PRV) infection has been reported to trigger excessive inflammatory responses in mice, swine, and in rare cases in humans, leading to acute viral encephalitis. However, the precise mechanisms by which PRV exacerbates host inflammation responses remain incompletely understood, and the potential role of PANoptosis in this pathogenic process has yet to be elucidated. Here, we demonstrate that PRV infection in different cell lines, murine primary macrophages and mice all results in activation of the PANoptotic signaling pathway and drives the formation of the core scaffold (caspase-8/ASC/RIPK3) within the PANoptosome. We observe that innate sensor proteins AIM2, Pyrin, and ZBP1 interact with the core scaffold protein ASC in PRV-infected THP-1 Mφ and co-localize with ASC. We further identify that IRF1 serves as the key transcription factor that is upregulated during PRV infection. Increased IRF1 translocates to the nucleus and binds directly to the promoter regions of innate sensor genes ZBP1 and AIM2, thereby elevating their gene expression. Ultimately, we discover that the genetic suppression of IRF1 expression and pharmacological blockade of PANoptosis markedly attenuate the extracellular release of pro-inflammatory mediators HMGB1 and IL-1β during PRV infection in vitro. Moreover, pharmacological inhibition of PANoptosis in vivo substantially reduces levels of HMGB1 and IL-1β in cerebral tissue of PRV-infected mice and effectively confers significant protection against PRV challenge, supporting an important role for PANoptosis in PRV pathogenesis. Collectively, our study not only provides a novel perspective on the pro-inflammatory mechanisms of PRV but also highlights that PANoptosis may be therapeutically targeted to improve viral infection outcomes. Introduction PANoptosis, a newly discovered form of regulated cell death (RCD), integrates key features of pyroptosis, apoptosis, and necroptosis, yet its mechanisms cannot be fully explained by any single cell death pathway1,2. The new concept, PANoptosis, was formally proposed by the research group of Kanneganti in 20193. The introduction of PANoptosis has challenged some traditional understandings of RCD. In the past decades, different types of RCD were considered to be independent processes, running in parallel and not interfering with each other4,5. The term “PAN-optosis” is formed by combining the initials of pyroptosis (P), apoptosis (A), and necroptosis (N) with the suffix “-optosis”, aiming to explain that this unique form of RCD integrates the characteristics of these three types of cell death1,6. PANoptosis is regulated by a large multimeric protein complex called the PANoptosome, the assembly of which is highly coordinated and dynamic7. Assembly of the PANoptosome is driven by homotypic and heterotypic interactions between essential domains of its molecular components1. To date, five PANoptosomes have been molecularly characterized, including the ZBP1-, AIM2-, RIPK1-, NLRP12-, and NLRC5-PANoptosome8–12. The phenomenon of “cross-talk” among pyroptosis, apoptosis, and necroptosis signaling pathways (PANoptosis) was discovered as early as 201613. Since then, an increasing number of reports have shown that PANoptosis occurs under various circumstances, such as microbial infection, autoimmune disease, homeostatic perturbations, and cancer14,15. Since PANoptosis is tightly regulated by the PANoptosome, functional defects or incomplete assembly of the PANoptosome can impair the activation of PANoptosis16. First, the execution of the PANoptosome’s biological functions strongly depends on protease and kinase activities16. A key example is caspase-8, which acts as a pivotal molecular switch in the PANoptosome17. The proteolytic activity of caspase-8 contributes to the broad regulation of pyroptotic, apoptotic, and necroptotic signaling pathways18. Second, the complete assembly of the PANoptosome not only relies on homotypic or heterotypic interactions among essential protein domains but also critically requires the assistance of regulatory factors such as caspase-6. Studies have revealed that caspase-6 binds to RIPK3 and enhances the interaction between ZBP1 and RIPK3, thereby promoting ZBP1-PANoptosome-driven PANoptosis19. To date, multiple host factors (e.g., Ceacam1, SMARCA4, PP6, RAVER1, and IRF1) involved in the regulation of PANoptosis have been identified through whole-genome CRISPR screening20–24. Among these, interferon regulatory factor 1 (IRF1) is the only known immune regulator contributing to ZBP1-, AIM2-, RIPK1-, as well as NLRP12-PANoptosome activation24. In this process, IRF1 primarily functions as an upstream transcriptional regulator of the PANoptotic signaling pathway. As previously reported, IRF1 controls gene transcription of NOS2, which is critical in the induction of TNF-α plus IFN-γ-mediated PANoptosis25. PRV, also known as suid alphaherpesvirus 1 (SuHV-1), is a key member of the genus Varicellovirus of the subfamily Alphaherpesvirinae within the family Herpesviridae26. PRV poses a substantial economic threat to the global swine industry by causing lethal infections in young piglets (characterized by neurological symptoms and up to 100% mortality), reproductive failure in sows (including abortion and stillbirths), and latent infections in adult pigs27,28. Histopathological examination of brain tissue in PRV-infected piglets exhibits hallmark features of viral encephalitis, including gliocytic hyperplasia (“glioma nodules”) and perivascular lymphocytic infiltration (“perivascular cuffing”)29,30. Beyond its impact on swine, PRV may exhibit zoonotic potential. Although human infection appears to be very rare, clinical human cases may involve neurological dysfunction, acute meningitis, and endophthalmitis31,32. Surveillance data reveal abnormally elevated leukocytes in the cerebrospinal fluid of patients with severe viral encephalitis, suggesting that PRV infection may induce hyperinflammatory responses in the human central nervous system33. In contrast to humans and higher primates, most other mammals, including mice, are very susceptible to lethal PRV infection. In murine models, PRV infection triggers systemic and lethal inflammatory responses, particularly cytokine storms in brain tissue—a critical factor contributing to rapid mortality34–36. Collectively, these findings indicate that in young piglets, mice, and very rarely in humans, PRV infection provokes excessive inflammatory responses. However, the precise mechanisms underlying PRV-mediated enhancement of host inflammation remain incompletely understood. As an innate host defense mechanism against viral infection, PANoptosis contributes to elimination of pathogens by facilitating the release of pro-inflammatory mediators to recruit immune cells37,38. However, dysregulated PANoptosis can drive detrimental inflammatory cascades, resulting in severe tissue damage37. Emerging evidence links PANoptosis to inflammatory diseases such as COVID-19, cytokine storm syndrome (CSS), and sepsis-associated encephalopathy (SAE)39–41. However, whether there is a direct relationship between PANoptosis and PRV-induced hyperinflammation remains unexplored. Centering on this issue, our study aims to address whether PRV infection triggers PANoptosis in vitro and in vivo and, if so, which molecular mechanism underlies PRV-induced PANoptosis and whether PRV infection enhances the host inflammatory response via PANoptosis. By addressing these questions, we not only decipher a novel regulatory axis on pro-inflammatory responses during PRV infection but also reveal PANoptosis as a potential therapeutic target to mitigate PRV-associated inflammation-driven disease symptoms. Results PRV can induce PANoptosis during its infection in vitro Previous studies have demonstrated that several microbial infections could induce PANoptosis in vitro8–10,13,25,42–44. To date, studies have reported that PRV infection in vitro could activate pyroptotic, apoptotic, and necroptotic signaling pathways45–47. We recently reported that PRV infection induced PANoptosis47. However, some phenotypes of PANoptosis, including the formation of PANoptosome, need to be further confirmed. Therefore, we systematically assessed the ability of PRV to induce PANoptosis during infection in vitro. The PANoptosome plays a critical role in the activation of PANoptosis48. Therefore, the formation of the PANoptosome serves as the most direct and robust evidence to determine whether PANoptosis occurs7. The PANoptosome is a large multimeric protein complex assembled through homotypic or heterotypic interactions between key structural domains of multiple protein molecules1. Caspase-8, ASC, and RIPK3, as relatively constant components of the PANoptosome, are identified as essential core scaffold proteins49. Consequently, most studies regard the spatial colocalization of caspase-8, ASC, and RIPK3 within cells as a biological marker to confirm the induction of PANoptosome formation9,12,38,49,50. To determine whether PANoptosome assembly occurs within individual cells during PRV infection, we initiated our studies using THP-1 cells, a commonly employed immortalized human monocytic cell line in PANoptosis research9,38,39. THP-1-derived macrophages (hereafter abbreviated as “THP-1 Mφ”) were obtained through phorbol 12-myristate 13-acetate (PMA)-induced differentiation9,38. Differentiated THP-1 Mφ were inoculated with the classical PRV strain JS-2020 (hereafter abbreviated as “cPRV”) at a multiplicity of infection (MOI) of 5. At 12 h post-infection (hpi), cPRV-infected THP-1 Mφ were subjected to confocal microscopy analysis. We observed colocalization of core PANoptosome scaffold proteins (i.e., RIPK3, ASC, and caspase-8) via high-resolution confocal laser scanning microscopy (CLSM). Additionally, quantitative analysis of PANoptosome formation at the single-cell level was conducted using ImageJ. The average proportion of positive THP-1 Mφ capable of forming PANoptosomes (ASC/Caspase-8/RIPK3 Speck+) across multiple fields of view was 22.4% (Fig. 1A and Supplementary Fig. 1A). These results indicate that PRV infection triggers the formation of the PANoptosome in infected THP-1 Mφ.Fig. 1PRV infection triggered PANoptosis in vitro.A THP-1 Mφ were infected with cPRV at an MOI of 5 and colocalization of RIPK3, caspase-8, and ASC within infected cells fixed at 12 hpi was assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. B THP-1 Mφ were infected with inactivated and infectious cPRV at an MOI of 5 and the lysates prepared at different time points were subjected to WB analysis for the activation of key PANoptotic biomarkers. C THP-1 Mφ were infected with vPRV at an MOI of 5 and the lysates prepared at different time points were subjected to WB analysis for the activation of key PANoptotic biomarkers. D THP-1 Mφ were infected with cPRV at different MOIs (0.1, 1, 5, and 10) and the lysates prepared at 18 hpi were subjected to WB analysis for the activation of key PANoptotic biomarkers. E CCK-8 assay. Analysis of the differential changes in the viability of THP-1 Mφ pretreated with individual and various combinatorial drugs following cPRV infection (5 MOI, 18 hpi). Scale bars, 20 μm. All data are expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). The data were analyzed statistically by software Graphpad Prism. Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; **, 0.001 < P-values < 0.01; ***, P-values < 0.001. PRV infection triggered PANoptosis in vitro. A THP-1 Mφ were infected with cPRV at an MOI of 5 and colocalization of RIPK3, caspase-8, and ASC within infected cells fixed at 12 hpi was assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. B THP-1 Mφ were infected with inactivated and infectious cPRV at an MOI of 5 and the lysates prepared at different time points were subjected to WB analysis for the activation of key PANoptotic biomarkers. C THP-1 Mφ were infected with vPRV at an MOI of 5 and the lysates prepared at different time points were subjected to WB analysis for the activation of key PANoptotic biomarkers. D THP-1 Mφ were infected with cPRV at different MOIs (0.1, 1, 5, and 10) and the lysates prepared at 18 hpi were subjected to WB analysis for the activation of key PANoptotic biomarkers. E CCK-8 assay. Analysis of the differential changes in the viability of THP-1 Mφ pretreated with individual and various combinatorial drugs following cPRV infection (5 MOI, 18 hpi). Scale bars, 20 μm. All data are expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). The data were analyzed statistically by software Graphpad Prism. Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; **, 0.001 < P-values < 0.01; ***, P-values < 0.001. PANoptosis integrates key molecular features of pyroptosis, apoptosis, and necroptosis1,2. Therefore, the activation of pyroptosis-, apoptosis-, and necroptosis-related biomarkers (e.g., GSDMD, caspase-3, caspase-8, and MLKL) within infected cells can serve as essential evidence supporting the activation of the PANoptotic signaling pathway during the PRV infection. To further assess whether PRV infection activates the PANoptotic signaling pathway, we infected THP-1 Mφ with infectious or UV-inactivated cPRV at a multiplicity of infection (MOI) of 5. Western blotting (WB) analysis revealed that only infectious cPRV infection induced the activation of pyroptotic, apoptotic, and necroptotic biomarkers, as evidenced by the detection of the N-terminal domain of cleaved GSDMD (GSDMD-NT), the small subunit of cleaved caspase-3 (caspase-3 p12), the small subunit of cleaved caspase-8 (caspase-8 p10), and the elevated phosphorylation of MLKL at serine 358 (p-MLKL S358) (Fig. 1B and Supplementary Fig. 1B–E). This finding implies that the activation of the PANoptotic signaling pathway during PRV infection depends on viral replication. Over the past years, variant PRV strains (genetically and antigenically different from classical PRV strains) have emerged in Asia, causing substantial economic problems29,51,52. To determine whether activation of the PANoptotic signaling pathway is a strain-independent host response to PRV infection, THP-1 Mφ were infected with recombinant GFP-expressing vPRV (HN1201-GFP, hereafter abbreviated as “vPRV”) at an MOI of 5. WB analysis demonstrated that vPRV infection triggered the activation of the PANoptotic signaling pathway, similar as observed during cPRV infection (Fig. 1C and Supplementary Fig. 1F–H), indicating that the activation of the PANoptotic signaling pathway during PRV infection is not strain-specific. To investigate whether PRV infection activates the PANoptotic signaling pathway at lower or higher MOIs, we infected THP-1 Mφ with cPRV at various MOIs (0.1, 1, 5, and 10). Cell lysates harvested at 18 hpi were subjected to immunoblot analysis to detect the activation of key biomarkers associated with pyroptosis, apoptosis, and necroptosis. Executioner proteins GSDMD, caspase-3, and MLKL were all activated at all tested MOIs (Fig. 1D). In addition, we also observed that the activation degree of these three biomarkers enhanced with increasing MOIs (Fig. 1D). This changing trend was reflected by the quantitative grayscale analysis of GSDMD-NT, caspase-3 p12, and p-MLKL S358 bands (Fig. 1D and Supplementary Fig. 1I–K). Since the mechanisms underlying PANoptosis cannot be fully explained by any single modality among pyroptosis, apoptosis, and necroptosis, blocking one of them individually fails to interfere with PANoptosis1,53,54. Consequently, comparing the effects of single versus combined pharmacological inhibition of pyroptosis, apoptosis, and necroptosis on the survival rate of PRV-infected cells can provide evidence as to whether PANoptosis is functionally activated. To explore whether individual or combined pharmacological inhibition of pyroptosis, apoptosis, and necroptosis can block PRV-induced cell death, three small-molecule drugs, Dimethyl Fumarate (DMF, pyroptosis inhibitor), Z-VAD-FMK (ZVAD, apoptosis inhibitor), and Necrosulfonamide (NSA, necroptosis inhibitor), were selected for subsequent assays55–57. The maximum non-toxic concentrations (MNTC) of DMF, ZVAD, and NSA in THP-1 Mφ, as determined by the CCK-8 assay, were 25, 100, and 6.25 μM, respectively (Supplementary Fig. 1L, M). Furthermore, drug combinations prepared at their corresponding MNTC values showed no toxicity against THP-1 Mφ. Based on the established MNTC values of these three drugs, THP-1 Mφ were pretreated for 2 h with individual drugs, dual-drug combinations, or triple-drug combinations, followed by cPRV infection (MOI 5) for 18 h. Cell viability was quantified using the CCK-8 assay. We found that individual inhibition of pyroptosis (DMF), apoptosis (ZVAD), or necroptosis (NSA) conferred a partial protective efficacy ranging from 60 to 80% (Fig. 1E). By contrast, the combined inhibition of these three modalities almost entirely blocked cPRV-induced cell death (more than 90%, P-values < 0.01) (Fig. 1E). Our data indicate that PANoptosis, rather than pyroptosis, apoptosis, or necroptosis alone, is functionally activated during PRV infection in vitro. Collectively, these findings reveal that PRV infection in vitro triggers PANoptosis in THP-1 Mφ. PRV infection in vitro can trigger PANoptosis in non-immune cells Originally, PANoptosis was first observed in macrophages13. For a period of time, it was considered a biological phenomenon specific to immune cells1. However, recent studies have revealed that PANoptosis can occur in non-immune cells (e.g., fibroblasts, endothelial cells, and cancer cells)58–61. PRV exhibits a broad host spectrum, capable of infecting various types of cells62–65. As a porcine neurotropic virus, PRV can also infect neural cells66,67. The activation of key PANoptotic markers in primary porcine alveolar macrophages (PAM) upon PRV infection was first confirmed by western blotting analysis, which was consistent with the observations in THP-1 Mφ (Supplementary Fig. 2A). However, whether PRV infection triggers PANoptosis in non-immune cells remains unknown. To address this, we selected wild boar fibroblast WSL cells (a wild boar lung-derived immortalized cell line) and murine astrocyte C8-D1A cells as non-immune cell models68,69. Both cell types were infected with cPRV at MOIs of 1 and 10, and the lysates were harvested at different time points. WB was performed to analyze the activation of key pyroptotic, apoptotic, and necroptotic biomarkers (executioner protein GSDMD, caspase-3, and MLKL). We detected the expression of GSDMD-(CT or NT) and caspase-3 p12 and the enhancement of p-MLKL (S345 or S358) in cPRV-infected C8-D1A and WSL cells, indicating that PRV infection also triggers PANoptotic signaling pathway in these non-immune cell types (Fig. 2A, B). To further confirm this, C8-D1A and WSL cells were infected with cPRV at an MOI of 1. Cells were subjected to confocal microscopy analysis at 12 hpi. Fixed cells stained with fluorescent antibodies targeting RIPK3 (AF594), ASC (AF488), and caspase-8 (AF546) and analyzed by CLSM. Similar to observations in THP-1 Mφ, core scaffold proteins of the PANoptosome (i.e., RIPK3, ASC, and caspase-8) were colocalized in the cPRV-infected C8-D1A and WSL cells, indicating that the PANoptosome assembles in PRV-infected non-immune cells. Meanwhile, the cell-based quantification of PANoptosome-positive cells was performed by using ImageJ. The average proportion of positive C8-D1A and WSL capable of forming PANoptosomes (ASC/Caspase-8/RIPK3 Speck+) across multiple fields of view were 18.7 and 24.0%, respectively (Fig. 2C, D and Supplementary Fig. 2B, C). Collectively, our data confirmed that PRV infection triggers PANoptosis in non-immune cells (C8-D1A and WSL) in vitro.Fig. 2PRV infection triggered PANoptosis in non-immune cells in vitro.A, B WB analysis for the activation of key PANoptotic biomarkers in A the astrocytes C8-D1A and B the fibroblast WSL. C, D Colocalization of RIPK3, ASC, and caspase-8 within C the astrocytes C8-D1A and D the fibroblast WSL were assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. Scale bars, 20 μm. Raw grayscale values of target proteins and GAPDH were quantified using software Fiji. For Phospho-MLKL, the ratio was derived by dividing its grayscale value by the corresponding Total-MLKL value. For other proteins, individual grayscale values were divided by the GAPDH value from the same sample. All datasets were further normalized to the control group (expressed as fold change relative to control) to enable cross-group comparisons. PRV infection triggered PANoptosis in non-immune cells in vitro. A, B WB analysis for the activation of key PANoptotic biomarkers in A the astrocytes C8-D1A and B the fibroblast WSL. C, D Colocalization of RIPK3, ASC, and caspase-8 within C the astrocytes C8-D1A and D the fibroblast WSL were assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. Scale bars, 20 μm. Raw grayscale values of target proteins and GAPDH were quantified using software Fiji. For Phospho-MLKL, the ratio was derived by dividing its grayscale value by the corresponding Total-MLKL value. For other proteins, individual grayscale values were divided by the GAPDH value from the same sample. All datasets were further normalized to the control group (expressed as fold change relative to control) to enable cross-group comparisons. PRV triggers PANoptosis during infection in vivo in mice Previous studies have predominantly focused on detecting the activation of the PANoptotic signaling pathway and the formation of the PANoptosome at the cellular level8,9,25,42,58. To address whether PRV infection in vivo can trigger PANoptosis, C57BL/6J mice were challenged intraperitoneally with cPRV at 1 × 103 TCID50 per mouse (Supplementary Fig. 3A). All mice were euthanized at 5 days post-infection (dpi). The brain, lung, spleen, liver, and kidney were harvested for partial freezing or fixation. First, PRV DNA copy numbers in various tissue samples were quantified by TaqMan-based qPCR, revealing high viral loads in the brain from cPRV-infected mice (P-values < 0.05) (Supplementary Fig. 3B). Subsequently, paraffin-embedded brain sections were prepared. Immunohistochemistry staining confirmed the distribution of abundant PRV antigen (gB) in brain tissue from cPRV-challenged mice (Supplementary Fig. 3C). Based on this mouse model, paraffin-embedded brain sections stained with fluorescent antibodies targeting RIPK3 (AF594), ASC (AF488), and caspase-8 (AF546) were analyzed by CLSM. We observed colocalization of core scaffold proteins (i.e., RIPK3, ASC, and caspase-8) within single cPRV-infected brain cells, which suggests that the PANoptosome assembles in brain tissue from cPRV-challenged mice. Furthermore, ImageJ was employed for the quantitative assessment of PANoptosome-positive cells. The average proportion of positive brain cells capable of forming PANoptosomes (ASC/Caspase-8/RIPK3 Speck+) across multiple fields of view was 23.3% (Fig. 3A and Supplementary Fig. 3D). In addition, the expression of GSDMD-CT and caspase-3 p12 and the phosphorylation of MLKL at serine 345 were further analyzed in the hippocampus (stripped from the brain) by WB. We detected substantial activation of executioner proteins GSDMD, caspase-3, and MLKL, which indicated that the PANoptotic signaling pathway is activated in brain tissue from cPRV-infected mice (Fig. 3B).Fig. 3PRV infection triggered PANoptosis in vivo.A Colocalization of RIPK3, ASC, and caspase-8 within brain tissue was assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. B WB analysis for the activation of key PANoptotic biomarkers in the brain tissue of mice challenged by cPRV at 1 × 103 TCID50 per mouse. C CCK-8 assay. Analysis of the differential changes in the cell viability of BMDMs pretreated with individual and various combinatorial drugs following PRV infection (5 MOI, 18 hpi). Scale bars, 20 μm. All data are expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). The data were analyzed statistically by software Graphpad Prism. Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; ***, P-values < 0.001, ns was considered statistically non-significant. Raw grayscale values of target proteins and GAPDH were quantified using software Fiji. For Phospho-MLKL, the ratio was derived by dividing its grayscale value by the corresponding Total-MLKL value. For other proteins, individual grayscale values were divided by the GAPDH value from the same sample. All datasets were further normalized to the control group (expressed as fold change relative to control) to enable cross-group comparisons. PRV infection triggered PANoptosis in vivo. A Colocalization of RIPK3, ASC, and caspase-8 within brain tissue was assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. B WB analysis for the activation of key PANoptotic biomarkers in the brain tissue of mice challenged by cPRV at 1 × 103 TCID50 per mouse. C CCK-8 assay. Analysis of the differential changes in the cell viability of BMDMs pretreated with individual and various combinatorial drugs following PRV infection (5 MOI, 18 hpi). Scale bars, 20 μm. All data are expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). The data were analyzed statistically by software Graphpad Prism. Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; ***, P-values < 0.001, ns was considered statistically non-significant. Raw grayscale values of target proteins and GAPDH were quantified using software Fiji. For Phospho-MLKL, the ratio was derived by dividing its grayscale value by the corresponding Total-MLKL value. For other proteins, individual grayscale values were divided by the GAPDH value from the same sample. All datasets were further normalized to the control group (expressed as fold change relative to control) to enable cross-group comparisons. To investigate whether PANoptosis can be functionally activated during PRV infection in primary cells, bone marrow-derived macrophages (BMDMs) were differentiated from primary murine bone marrow cells using macrophage colony-stimulating factor (M-CSF)70. The MNTC of the pyroptosis inhibitor DMF, apoptosis inhibitor ZVAD, and necroptosis inhibitor NSA were determined in BMDMs using the CCK-8 assay (Supplementary Fig. 3E). In addition, the lack of cytotoxicity of combinatorial drugs was also confirmed in BMDMs using the CCK-8 assay (Supplementary Fig. 3F). On this basis, BMDMs were pretreated for 2 h with individual drugs, dual-drug combinations, or triple-drug combinations, followed by cPRV infection (5 MOI) for 18 h. Cell viability was quantified using the CCK-8 assay. We found that individual inhibition of pyroptosis (DMF), apoptosis (ZVAD), or necroptosis (NSA) conferred a partial protective efficacy ranging from 60 to 70% (Fig. 3C). By contrast, the combined inhibition of these three modalities almost entirely blocked cPRV-induced cell death, exhibiting a superior protective efficacy (more than 90%, P-values < 0.001) (Fig. 3C). Collectively, these findings revealed that PRV infection triggers PANoptosis in brain tissue from infected C57BL/6J mice and in primary murine BMDMs. Innate sensors AIM2, Pyrin, and ZBP1 participate in PANoptosome formation during PRV infection in vitro Recent studies have revealed that herpes simplex virus type 1 (HSV-1) induces the formation of a complex composed of AIM2, Pyrin, and ZBP1 to drive PANoptosis during infection in vitro9. Further investigation demonstrated that AIM2 plays a predominant role in HSV-1-activated PANoptosome assembly, while Pyrin and ZBP1 act cooperatively to support this process9. Like HSV-1, PRV is also a key member of the Alphaherpesvirinae subfamily26. However, whether PRV similarly depends on these sensor proteins (i.e., AIM2, Pyrin, and ZBP1) to mediate the assembly of the PANoptosome remains unclear. To test this hypothesis, THP-1 Mφ were infected with cPRV at an MOI of 5 and subjected to confocal microscopy analysis at 12 hpi. Fluorescent antibodies targeting AIM2 (AF546), ZBP1 (AF594), Pyrin (AF647), and ASC (AF488) were applied for immunofluorescence staining, followed by analysis via CLSM. Notably, colocalization of innate sensor proteins (AIM2, Pyrin, and ZBP1) with the core scaffold protein ASC was observed in single PRV-infected THP-1 Mφ. In parallel, cell-based quantification of PANoptosome was carried out with ImageJ. The average proportion of THP-1 Mφ that formed PANoptosomes (ASC/AIM2/Pyrin/ZBP1 Speck+) across multiple fields of view was 21.3% (Fig. 4A and Supplementary Fig. 3G). Our data indicate that AIM2, Pyrin, and ZBP1 are components of the PRV-induced PANoptosome and may participate in its assembly.Fig. 4The innate immune sensor proteins AIM2, Pyrin, and ZBP1 were involved in the assembly of the PANoptosome.A THP-1 Mφ were infected with cPRV at an MOI of 5 and colocalization of AIM2, Pyrin, ZBP1, and ASC within infected THP-1 Mφ fixed at 12 hpi was assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. B THP-1 Mφ were infected with cPRV at an MOI of 5 and the lysates prepared at 12 hpi were subjected to co-immunoprecipitation (Co-IP) analysis. Scale bars, 20 μm. The innate immune sensor proteins AIM2, Pyrin, and ZBP1 were involved in the assembly of the PANoptosome. A THP-1 Mφ were infected with cPRV at an MOI of 5 and colocalization of AIM2, Pyrin, ZBP1, and ASC within infected THP-1 Mφ fixed at 12 hpi was assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. B THP-1 Mφ were infected with cPRV at an MOI of 5 and the lysates prepared at 12 hpi were subjected to co-immunoprecipitation (Co-IP) analysis. Scale bars, 20 μm. To further validate this, co-immunoprecipitation (Co-IP) assays were conducted. THP-1 Mφ were infected with cPRV at an MOI of 5. Lysates prepared at 12 hpi were subjected to Co-IP employing an ASC-specific rabbit monoclonal antibody to capture protein complexes interacting with the ASC selectively. Strikingly, AIM2, Pyrin, ZBP1, Caspase-1, Caspase-8, and RIPK1, RIPK3, and FADD were all detected in the ASC-precipitated protein complexes (Fig. 4B). Our data indicate that AIM2, Pyrin, ZBP1, Caspase-1, Caspase-8, and RIPK1, RIPK3, and FADD all interacted with the core scaffold protein ASC in the PANoptosome during PRV infection of THP-1 Mφ. Since the expression of ASC and Caspase-8 did not change significantly, we speculate that PRV infection may induce the speck assembly of preexisting proteins rather than upregulating expression of these proteins. Collectively, these findings confirmed that the innate sensor proteins AIM2, Pyrin, and ZBP1 are associated with the PANoptosome in PRV-infected THP-1 Mφ. Transcription factor IRF1 directly upregulates ZBP1 and AIM2 gene expression to enhance the activation of the PANoptotic signaling pathway Previous studies have demonstrated that the immune regulator IRF1 contributes to the activation of the ZBP1- and NLRP12-PANoptosome and PANoptosis24. Mechanistically, IRF1 acts as a transcriptional regulator, upregulating the expression of critical sensor proteins ZBP1 and NLRP12 in the PANoptotic signaling pathway11,71. In our study, we observed the association of multiple sensor proteins (i.e., AIM2, Pyrin, and ZBP1) with the PANoptosome during PRV infection. However, whether IRF1 contributes to the PRV-activated PANoptotic signaling pathway by regulating the expression AIM2, Pyrin, and/or ZBP1 remained unexplored. To address this, we first investigated the expression of IRF1, AIM2, MEFV, and ZBP1 during PRV infection (Supplementary Fig. 4A–F). THP-1 Mφ were infected with cPRV at an MOI of 5. Cell lysates harvested at various time points were used for subsequent extraction of total protein and total RNA, respectively. WB analysis showed that the protein levels of IRF1, AIM2, Pyrin, and ZBP1 were significantly increased at 9–12 hpi (P-values < 0.05) (Supplementary Fig. 4A, B). qPCR analysis showed that mRNA levels of IRF1, AIM2, MEFV, and ZBP1 exhibited a significant increase at 6–18 hpi (P-values < 0.05) (Supplementary Fig. 4C–F). These findings indicate that PRV infection promotes the expression of IRF1, AIM2, MEFV, and ZBP1. However, mRNA levels of MEFV did not show an equally pronounced upregulation as observed for AIM2 and ZBP1 (i.e., no significant upregulation at either 6–9, 9–12, or 12–18 hpi), suggesting that the transcriptional regulation of the MEFV gene may display differences compared to that of the AIM2 and ZBP1 genes (P-values < 0.05) (Supplementary Fig. 4C–F). Previous studies have revealed that IRF1 could act as a transcription factor (TF) driving expression of guanylate-binding proteins (GBPs), thereby contributing to the activation of the AIM2 inflammasome during F. novicida infection72. Therefore, we investigated whether IRF1 may also act as TF driving expression of AIM2, MEFV, and ZBP1 to promote activation of the PANoptotic signaling pathway during PRV infection. To address this, we first examined the subcellular localization of IRF1 during PRV infection. THP-1 Mφ were infected with cPRV at an MOI of 5. At 12 hpi, the cells were fixed and subjected to immunofluorescence using a monoclonal rabbit anti-IRF1 antibody and a monoclonal mouse anti-PRV glycoprotein B (gB) antibody. Confocal microscopy analysis revealed striking nuclear translocation of IRF1 at 18 hpi (Fig. 5A) a phenomenon that was also observed in PRV-infected non-immune Vero cells (0.5 MOI, 9 hpi) (Supplementary Fig. 5A).Fig. 5Knockdown of IRF1 reduced the ZBP1 and AIM2 expression and impaired the PANoptotic signaling during PRV infection.A Nuclear translocation of IRF1 assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. B THP-1 Mφ were infected with cPRV at an MOI of 5 and the lysates prepared at multiple time points (e.g., 3, 6, 9, 12, 18, 24 hpi) were further separated into the nuclear and the cytoplasmic fractions. The expression of IRF1 in the cytoplasm and the nucleus was determined by western blotting analysis, respectively. C THP-1 Mφ were infected with cPRV at an MOI of 5 and the lysates prepared at 18 hpi were subjected to DNA pulldown analysis. D–F Relative luciferase activities in HEK-293T cells co-transfected with the pRL-TK, pcDNA3.1-IRF1, and D pGL3-Basic-AIM2 or E pGL3-ZBP1 or F pGL3-Basic-MEFV. Firefly luciferase activity was normalized to Renilla luciferase activity. G WB analysis for the effect of IRF1 knockdown on the expression levels of sensor proteins (e.g., AIM2, Pyrin, ZBP1) and the activation of PANoptotic biomarkers during PRV infection (5 MOI, 18 hpi). Scale bars, 20 μm. All data are expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). The data were analyzed statistically by software Graphpad Prism. Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; **, 0.001 < P-values < 0.01; ***, P-values < 0.001, ns was considered statistically non-significant. Raw grayscale values of target proteins and GAPDH were quantified using software Fiji. For Phospho-MLKL, the ratio was derived by dividing its grayscale value by the corresponding Total-MLKL value. For other proteins, individual grayscale values were divided by the GAPDH value from the same sample. All datasets were further normalized to the control group (expressed as fold change relative to control) to enable cross-group comparisons. Knockdown of IRF1 reduced the ZBP1 and AIM2 expression and impaired the PANoptotic signaling during PRV infection. A Nuclear translocation of IRF1 assessed using fluorescent antibody staining, with results observed under a high-resolution confocal laser scanning microscope. B THP-1 Mφ were infected with cPRV at an MOI of 5 and the lysates prepared at multiple time points (e.g., 3, 6, 9, 12, 18, 24 hpi) were further separated into the nuclear and the cytoplasmic fractions. The expression of IRF1 in the cytoplasm and the nucleus was determined by western blotting analysis, respectively. C THP-1 Mφ were infected with cPRV at an MOI of 5 and the lysates prepared at 18 hpi were subjected to DNA pulldown analysis. D–F Relative luciferase activities in HEK-293T cells co-transfected with the pRL-TK, pcDNA3.1-IRF1, and D pGL3-Basic-AIM2 or E pGL3-ZBP1 or F pGL3-Basic-MEFV. Firefly luciferase activity was normalized to Renilla luciferase activity. G WB analysis for the effect of IRF1 knockdown on the expression levels of sensor proteins (e.g., AIM2, Pyrin, ZBP1) and the activation of PANoptotic biomarkers during PRV infection (5 MOI, 18 hpi). Scale bars, 20 μm. All data are expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). The data were analyzed statistically by software Graphpad Prism. Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; **, 0.001 < P-values < 0.01; ***, P-values < 0.001, ns was considered statistically non-significant. Raw grayscale values of target proteins and GAPDH were quantified using software Fiji. For Phospho-MLKL, the ratio was derived by dividing its grayscale value by the corresponding Total-MLKL value. For other proteins, individual grayscale values were divided by the GAPDH value from the same sample. All datasets were further normalized to the control group (expressed as fold change relative to control) to enable cross-group comparisons. To corroborate these findings, THP-1 Mφ were infected with cPRV at an MOI of 5 and cell lysates were harvested at different time points and subjected to a separation of nuclear and cytoplasmic proteins. WB analysis demonstrated a progressive decrease of cytoplasmic IRF1 concomitant with an accumulation of nuclear IRF1 throughout PRV infection (Fig. 5B). Taken together, these data indicate that PRV infection drives the nuclear import of IRF1, where it may act as a transcription factor. To investigate whether IRF1 can directly bind to the promoter region of AIM2, MEFV, and/or ZBP1, DNA pull-down assays were conducted. First, biotinylated promoter fragments of AIM2, MEFV, or ZBP1 were amplified, respectively, using universal 5′-biotin labeled primer pairs. These fragments, containing promoter sequences of AIM2, MEFV, or ZBP1, were individually conjugated to streptavidin-coated magnetic beads and subsequently utilized to capture interacting proteins from cell lysates. The cell lysates were prepared by lysing THP-1 Mφ infected with cPRV at an MOI of 5 for 18 h, using an NP-40 lysis buffer. Strikingly, WB analysis showed that IRF1 was only detected in the AIM2 or ZBP1 promoter fragments-precipitated proteins (Fig. 5C). These data indicate that IRF1 exhibited binding specificity to the promoter sequences of AIM2 and ZBP1 while showing no detectable interaction with the promoter region of MEFV. To investigate whether IRF1 can activate the transcriptional activity of the AIM2, MEFV, and/or ZBP1 promoters, dual-luciferase reporter assays were performed. The promoter sequences of the AIM2, MEFV, and ZBP1 genes were cloned into the pGL3-Basic vector to construct luciferase reporter plasmids (i.e., pGL3-Basic-AIM2, pGL3-Basic-MEFV, and pGL3-Basic-ZBP1), respectively. Subsequently, pGL3-Basic-AIM2, pGL3-Basic-MEFV, or pGL3-Basic-ZBP1 were individually co-transfected into HEK-293T cells along with the Renilla luciferase reporter plasmid (pRL-TK) and an IRF1 eukaryotic expression plasmid (pcDNA3.1-IRF1). Cell lysates were harvested at 24 h post-transfection, and the activities of firefly and Renilla luciferase were sequentially measured using a dual luciferase reporter assay kit. Relative luciferase activity revealed that transient expression of IRF1 significantly enhanced the transcription of pGL3-Basic-AIM2 and pGL3-Basic-ZBP1, leading to increased expression of firefly luciferase (Fig. 5D, E). In contrast, transient expression of IRF1 failed to promote the transcription of pGL3-Basic-MEFV (Fig. 5F). Furthermore, to assess the specificity of IRF1-mediated regulation, we performed a control experiment in which pcDNA3.1-IRF7 was co-transfected into HEK-293T cells with pGL3-Basic-AIM2, pGL3-Basic-ZBP1, or pGL3-Basic-MEFV, respectively. The results indicated that transient expression of IRF7 did not enhance the transcription of pGL3-Basic-AIM2, pGL3-Basic-ZBP1, or pGL3-Basic-MEFV (Supplementary Fig. 5B–D). These findings indicate that IRF1 activates the transcriptional activity of AIM2 and ZBP1 promoters, initiating their gene expression. To validate the regulatory role of IRF1 on the expression of sensor proteins (e.g., AIM2, Pyrin, and/or ZBP1) and the activation of the PANoptotic signaling pathway, an IRF1 knockdown THP-1 cell line (IRF1-KD THP-1) was generated using lentivirus-delivered shRNA-IRF1. The established knockdown cell line (IRF1-KD THP-1) demonstrated effective suppression of IRF1 expression, achieving a 70% reduction in IRF1 mRNA levels and a 50% reduction in IRF1 protein levels, compared to wild-type (WT) THP-1 (Supplementary Fig. 5E–G). Based on this, IRF1-KD THP-1 Mφ were infected with cPRV at an MOI of 5 and cell lysates were collected at 18 hpi and further subjected to WB analysis for the expression of sensor proteins (AIM2, Pyrin, and ZBP1) and the activation of the PANoptotic signaling pathway. We found that expression of both AIM2 and ZBP1 in the IRF1-KD THP-1 Mφ were significantly reduced in the absence of PRV infection, while the expression of Pyrin remained unaffected (Fig. 5G and Supplementary Fig. 5H). In addition, we also noticed that the knockdown of IRF1 markedly suppressed the upregulated expression of AIM2 and ZBP1 during PRV infection, with no observable effect on Pyrin (Fig. 5G). Similar results were obtained on mRNA level by using RT-qPCR (Supplementary Fig. 5I–L). Notably, knockdown of IRF1 also significantly inhibited the activation of the PANoptotic signaling pathway (pyroptosis, apoptosis, and necroptosis) (Fig. 5G and Supplementary Fig. 5M). Collectively, our findings indicate that IRF1 directly binds to the promoter regions of AIM2 and ZBP1 to drive their gene expression, thereby enhancing the activation of the PANoptotic signaling pathway during PRV infection. PRV infection exacerbates the release of pro-inflammatory mediators HMGB1 and IL-1β by triggering PANoptosis High mobility group box 1 protein (HMGB1) and interleukin-1 beta (IL-1β) exhibit unique release mechanisms: HMGB1 can be passively released through plasma membrane rupture mediated by necroptosis, whereas IL-1β relies on the pore-forming activity of GSDMD in the canonical pyroptotic signaling pathway73–76. The passive release mediated by lytic cell death is an uncontrolled process that leads to the direct, excessive, and rapid discharge of cellular contents (e.g., HMGB1 and IL-1β) into the extracellular space, thereby exacerbating the development of inflammatory responses77. The excessive release of HMGB1 and IL-1β is commonly observed during viral infections78–81. Recent advances have revealed that SARS-CoV-2 infection induces PANoptosis, which exacerbates the release of HMGB182. However, whether PANoptosis can simultaneously mediate the dual excessive release of HMGB1 and IL-1β during PRV infection remains unknown. To address this, we first examined the level of the pro-inflammatory mediators HMGB1 and IL-1β in the supernatant during PRV infection. THP-1 Mφ were infected with cPRV at an MOI of 5, and cell culture supernatant was collected at various time points after PRV infection. WB and ELISA analysis demonstrated that the level of HMGB1 and IL-1β in the cell culture supernatant exhibited a significant gradual increase following PRV infection (P-values < 0.05) (Supplementary Fig. 6A–D). Moreover, the expression of the immature IL-1β precursor (pro-IL-1β) was detected in the supernatant (Supplementary Fig. 6A and D). These findings indicate that PRV infection triggers the extracellular release of the pro-inflammatory mediators HMGB1 and IL-1β. To investigate whether the extracellular release of the pro-inflammatory mediators HMGB1 and IL-1β during PRV infection is associated with the induction of PANoptosis, we performed in vitro pharmacological intervention experiments targeting the PANoptotic signaling pathway. Again, THP-1 Mφ were pretreated for 2 h with individual drugs, dual-drug combinations, or triple-drug combinations, followed by cPRV infection (5 MOI) for 18 h. Cell lysates and culture supernatant were harvested at the indicated time point for WB and ELISA analysis, respectively. WB analysis demonstrated that pretreatment of THP-1 Mφ with a combination of the three cell death inhibitors (i.e., DMF, ZVAD, and NSA) significantly suppressed the activation of the PANoptotic signaling pathway during PRV infection (Fig. 6A and Supplementary Fig. 6E). Furthermore, both WB and ELISA analyses revealed that this combinatorial drug strategy markedly reduced the extracellularly released levels of HMGB1 and IL-1β induced by PRV infection (P-values < 0.05) (Fig. 6A, C and D). To further validate these findings, THP-1 cell lines in which IRF1 expression was silenced (IRF1-KD THP-1) or in which IRF1 was overexpressed (IRF1-OE THP-1) were constructed. Cells were infected with cPRV at an MOI of 5. Cell lysates and culture supernatant were collected at 18 hpi for WB and ELISA analysis. WB analysis revealed that the knockdown of IRF1 expression effectively suppressed the activation of the PANoptotic signaling pathway triggered by PRV infection, whereas IRF1 overexpression markedly enhanced its activation (Fig. 6B and Supplementary Fig. 6F). Furthermore, both WB and ELISA analyses demonstrated that IRF1 knockdown significantly attenuated the extracellular release of the pro-inflammatory mediators HMGB1 and IL-1β induced by PRV infection, while IRF1 overexpression substantially increased their release (P-values < 0.05) (Fig. 6B, E and F). These data indicate that PRV infection in vitro exacerbated the extracellular release of HMGB1 and IL-1β via PANoptosis.Fig. 6Inhibition of PANoptotic signaling reduced the release of pro-inflammatory mediators triggered by PRV infection.A WB analysis for the differential changes in the level of pro-inflammatory mediators HMGB1 and pro-IL-1β released from THP-1 Mφ during PRV infection (5 MOI, 18 hpi) following individual and various combinatorial drugs pretreatments. B WB analysis for the differential changes in the level of pro-inflammatory mediators HMGB1 and IL-1β released from THP-1 Mφ with IRF1 knockdown and overexpression during PRV infection (5 MOI, 18 hpi). C, D ELISA analysis for differential changes in the level of pro-inflammatory mediators C HMGB1 and D IL-1β released from THP-1 Mφ during PRV infection (5 MOI, 18 hpi) following individual and various combinatorial drugs pretreatments. E, F ELISA analysis for the differential changes in the level of pro-inflammatory mediators E HMGB1 and F IL-1β released from THP-1 Mφ with IRF1 knockdown and overexpression during PRV infection (5 MOI, 18 hpi). G Survival curve. Analysis of the differential survival rates of C57BL/6J mice pretreated with individual and various combinatorial drugs following cPRV infection (1 × 103 TCID50 per mouse). H, I ELISA analysis for differential changes in the level of pro-inflammatory mediators H HMGB1 and I IL-1β within brain tissue from PRV-challenged C57BL/6J mice (1 × 103 TCID50 per mouse) following individual and various combinatorial drugs pretreatments. J PRV DNA copy number in brain tissue collected from C57BL/6J mice pretreated with individual and various combinatorial drugs following cPRV infection (1 × 103 TCID50 per mouse) were analyzed using TaqMan-based qPCR. All data are expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). The data were analyzed statistically by software Graphpad Prism. Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; **, 0.001 < P-values < 0.01; ***, P-values < 0.001, ns was considered statistically non-significant. Raw grayscale values of target proteins and GAPDH were quantified using software Fiji. For Phospho-MLKL, the ratio was derived by dividing its grayscale value by the corresponding Total-MLKL value. For other proteins, individual grayscale values were divided by the GAPDH value from the same sample. All datasets were further normalized to the control group (expressed as fold change relative to control) to enable cross-group comparisons. Inhibition of PANoptotic signaling reduced the release of pro-inflammatory mediators triggered by PRV infection. A WB analysis for the differential changes in the level of pro-inflammatory mediators HMGB1 and pro-IL-1β released from THP-1 Mφ during PRV infection (5 MOI, 18 hpi) following individual and various combinatorial drugs pretreatments. B WB analysis for the differential changes in the level of pro-inflammatory mediators HMGB1 and IL-1β released from THP-1 Mφ with IRF1 knockdown and overexpression during PRV infection (5 MOI, 18 hpi). C, D ELISA analysis for differential changes in the level of pro-inflammatory mediators C HMGB1 and D IL-1β released from THP-1 Mφ during PRV infection (5 MOI, 18 hpi) following individual and various combinatorial drugs pretreatments. E, F ELISA analysis for the differential changes in the level of pro-inflammatory mediators E HMGB1 and F IL-1β released from THP-1 Mφ with IRF1 knockdown and overexpression during PRV infection (5 MOI, 18 hpi). G Survival curve. Analysis of the differential survival rates of C57BL/6J mice pretreated with individual and various combinatorial drugs following cPRV infection (1 × 103 TCID50 per mouse). H, I ELISA analysis for differential changes in the level of pro-inflammatory mediators H HMGB1 and I IL-1β within brain tissue from PRV-challenged C57BL/6J mice (1 × 103 TCID50 per mouse) following individual and various combinatorial drugs pretreatments. J PRV DNA copy number in brain tissue collected from C57BL/6J mice pretreated with individual and various combinatorial drugs following cPRV infection (1 × 103 TCID50 per mouse) were analyzed using TaqMan-based qPCR. All data are expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). The data were analyzed statistically by software Graphpad Prism. Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; **, 0.001 < P-values < 0.01; ***, P-values < 0.001, ns was considered statistically non-significant. Raw grayscale values of target proteins and GAPDH were quantified using software Fiji. For Phospho-MLKL, the ratio was derived by dividing its grayscale value by the corresponding Total-MLKL value. For other proteins, individual grayscale values were divided by the GAPDH value from the same sample. All datasets were further normalized to the control group (expressed as fold change relative to control) to enable cross-group comparisons. To further validate these findings in vivo, we first examined the level of pro-inflammatory mediators HMGB1 and IL-1β in mice upon PRV infection. C57BL/6J mice were challenged intraperitoneally with cPRV at 1 × 103 TCID50 per mouse (Supplementary Fig. 3A). All mice were euthanized at 5 dpi. Serum from PRV-infected mice was collected and homogenates of tissues were prepared by homogenizing the brain of PRV-challenged mice using a tissue grinder. All samples were subjected to ELISA, revealing that PRV infection significantly elevated the level of the pro-inflammatory mediators HMGB1 and IL-1β in the serum and brain tissue of PRV-infected mice (Supplementary Fig. 7A–D). Furthermore, paraffin-embedded sections of brain tissue were prepared. Hematoxylin-eosin (HE) staining demonstrated the presence of “perivascular cuffing” (i.e., perivascular infiltration of inflammatory cells in single or multiple layers) in the brain tissue of infected mice, indicating the development of non-suppurative encephalitis induced by PRV infection in vivo (Supplementary Fig. 7E). These findings collectively demonstrate the successful establishment of a murine model of PRV-induced viral encephalitis in vivo. Based on the inflammatory model induced by PRV infection in mice, we performed a survival analysis in pharmacological intervention experiments in vivo targeting the PANoptotic signaling pathway. C57BL/6J mice were either pretreated with DMSO diluent or pretreated for 12 h with individual drugs, dual-drug combinations, or triple-drug combinations, followed by cPRV infection at 1 × 103 TCID50 per mouse (Supplementary Fig. 7F). Drug (or DMSO) administration was subsequently performed every 24 h until day 3 after PRV challenge. Clinical monitoring of mice continued through day 14 after PRV challenge, with rigorous daily documentation of clinical manifestations and survival outcomes across experimental groups. Survival curves were generated from recorded data and subjected to statistical significance analysis. Our results demonstrated that compared to individual inhibition of pyroptosis, apoptosis, or necroptosis, the combined administration of these three small-molecule inhibitors provided enhanced protection in PRV-challenged mice, significantly improving post-infection survival rates (P-values < 0.05) (Fig. 6G). Our data indicate that PANoptosis, rather than solely pyroptosis, apoptosis, or necroptosis, was functionally activated during PRV infection in vivo. In a follow-up assay, C57BL/6J were again pretreated with DMSO diluent or pretreated for 12 h with individual drugs, dual-drug combinations, or triple-drug combinations, followed by cPRV infection at 1 × 103 TCID50 per mouse (Supplementary Fig. 7G). Drug (or DMSO) administration was subsequently performed every 24 h until day 3 after PRV challenge. All mice were euthanized at 5 dpi according to the results of the survival analysis. Homogenates of tissues were prepared by homogenizing the brain of PRV-challenged mice using a tissue grinder. ELISA analysis showed that pretreatment of C57BL/6J mice with a combination of three cell death inhibitors (i.e., DMF, ZVAD, and NSA) significantly attenuated the level of HMGB1 and IL-1β in the brain tissue during PRV infection (P-values < 0.05) (Fig. 6H, I). These findings indicated that PRV infection in vivo exacerbated the extracellular release of HMGB1 and IL-1β via PANoptosis. qPCR analysis demonstrated that pretreatment of C57BL/6J mice with a combination of three cell death inhibitors (i.e., DMF, ZVAD, and NSA) significantly reduced the viral copy number in the brain tissue during PRV infection (P-values < 0.05) (Fig. 6J). This finding suggested that PANoptosis may facilitate viral replication within the brain tissue of infected mice. Collectively, our data supported that PRV infection exacerbates the release of pro-inflammatory mediators HMGB1 and IL-1β by triggering PANoptosis. Discussion PANoptosis serves as an innate host defense mechanism against viral infection, as it triggers the infiltration of immune cells to remove infectious agents. However, excessive PANoptosis, without benefits to the host, drives uncontrolled inflammatory responses, leading to tissue damage and even organ failure. In this study, we show that PRV infection induces PANoptosis both in immune cells and in non-immune cells. To the best of our knowledge, we provide the first in vivo evidence in murine models demonstrating that PRV infection triggers PANoptosis in brain tissue. Mechanistically, we observed that three innate sensor proteins (AIM2, Pyrin, and ZBP1) participate in PANoptosome assembly within individual THP-1 Mφ during PRV infection. Based on previous studies, we have filled remaining gaps in the role of IRF1 in the PANoptotic signaling pathway. Our studies emphasize that IRF1 functions as a critical transcription factor located upstream of PANoptotic signaling, undergoes nuclear translocation during PRV infection and directly binds to the promoter regions of AIM2 and ZBP1 genes, thereby initiating their transcription. Ultimately, compelling evidence indicates that PRV infection triggers the excessive release of pro-inflammatory mediators (e.g., HMGB1 and IL-1β) in vitro and in vivo mediated by PANoptosis. Notably, a combination therapy targeting PANoptosis-related signaling pathways (pyroptosis inhibitor Dimethyl Fumarate, apoptosis inhibitor Z-VAD-FMK, and necroptosis inhibitor Necrosulfonamide, administered as a pretreatment before PRV infection) significantly attenuates PRV-induced release of HMGB1 and IL-1β in vitro, reduces cerebral levels of these mediators in PRV-infected mice, and protects against lethal PRV challenge in vivo (Supplementary Fig. 8). These findings provide a novel perspective towards the underlying mechanisms by which PRV infection enhances inflammatory response. When investigating PRV-induced activation of PANoptosis in THP-1 Mφ, our study revealed a colocalization of core PANoptosome scaffold proteins (i.e., RIPK3, ASC, and caspase-8) and a temporal sequence in the activation of the three involved cell death pathways (pyroptosis, apoptosis, and necroptosis) (Fig. 1A, B). Specifically, necroptotic signaling (evidenced by increased phosphorylation of human MLKL at the S358 site) was significantly activated during 6–24 hpi with cPRV at an MOI of 5 (Fig. 1B). Apoptotic signaling (indicated by cleavage of pro-caspase-3 into the active p12 subunit) was markedly activated during 18–24 hpi, while pyroptotic signaling (characterized by cleavage of full-length GSDMD into the N-terminal p30 fragment) was predominantly activated during 12–24 hpi (Fig. 1B). These findings demonstrate that necroptotic signaling is the first pathway activated during early PRV infection (6–12 hpi), peaking at 12 hpi, during which pyroptosis and apoptosis remained minimally active (Fig. 1B). Subsequently, necroptotic signaling gradually diminished after 12hpi, whereas pyroptosis and apoptosis signaling progressively intensified (Fig. 1B). A similar temporal activation pattern was observed during PRV infection of WSL cells in vitro (Fig. 2B). In fact, these findings align closely with the core concept of PANoptosis: during PANoptosis, the observed biological effects in the aforementioned phenotypes cannot be solely attributed to pyroptosis, apoptosis, or necroptosis individually83. Instead, they arise from the coordinated interplay of multiple cell death mechanisms, forming an integrated defense strategy that effectively circumvents pathogen-mediated suppression of any single death pathway, thereby preventing immune evasion84. During PRV infection, a dynamic interplay exists between the host and virus. Our data suggest that, while PRV suppresses and delays pyroptosis and apoptosis signaling, necroptosis is activated as an alternative pathway. This phenomenon—where blocking one or some cell death pathways fails to prevent PRV-induced cell death—exemplifies the hallmark features of PANoptosis. Critically, pharmacological intervention experiments further support this interpretation (Fig. 1E). Pretreatment of THP-1 Mφ with inhibitors targeting pyroptosis, apoptosis, or necroptosis individually only partially blocked PRV-induced cell death (60–80% inhibition) (Fig. 1E), while simultaneous inhibition of all three pathways achieved significantly higher efficacy (>90% inhibition, P-values < 0.001), underscoring the necessity of combinatorial targeting to disrupt PANoptosis-driven cell death (Fig. 1E). Previous studies have shown that IRF1 serves as a transcription factor that indirectly activates the AIM2 inflammasome by upregulating the expression of guanylate-binding proteins (GBPs)72. However, in the context of PANoptosis, researchers primarily utilized IRF1-knockout cellular and murine models to confirm IRF1’s essential role in PANoptosis and its function as a transcriptional regulator enhancing the expression of key sensor genes within the PANoptosome24. Nevertheless, these studies did not resolve whether IRF1 acts as a transcription factor or a regulatory cofactor upstream of PANoptotic signaling pathways, nor whether its effects are direct or indirect. The current study reveals that IRF1 functions as a transcription factor during PRV-induced PANoptosis, directly binding to the promoter regions of the PANoptotic sensor genes ZBP1 and AIM2 to enhance their transcription (Fig. 5). Notably, IRF1 exhibited a stronger activation of the ZBP1 promoter compared to the AIM2 promoter (Fig. 5D, E). Furthermore, PRV infection significantly enhanced the binding affinity of IRF1 to the ZBP1 promoter (P-values < 0.01) (Fig. 5C), though the underlying mechanism remains to be elucidated. Of note, pigs lack functional AIM2 due to a frameshift mutation, fundamentally altering their cytosolic DNA-sensing capabilities compared to human and mice85,86. However, in our study, both IFA and WB analyses confirmed that PRV-induced the formation of PANoptosome and the occurrence of PANoptosis in infected wild boar lung cells (WSL cells) (Fig. 2B, D). Consequently, future research should focus on utilizing multiplexed gene knockout/knockdown technology to identify which key innate sensor protein primarily mediates the assembly of the PANoptosome during PRV infection in mouse cells and determine the compensatory molecule(s) that functionally substitute for AIM2 deficiency in swine in this respect. PANoptosis-mediated dysregulated release of pro-inflammatory mediators is closely associated with various inflammatory diseases, including SARS-CoV-2-induced COVID-19, sepsis, and hemophagocytic lymphohistiocytosis (HLH)40. Among these mediators, HMGB1 and IL-1β are critically implicated in exacerbating inflammatory responses87–89. Our study confirms that PANoptosis simultaneously facilitates the passive release of HMGB1 and IL-1β in vitro and in vivo. Notably, HMGB1 and IL-1β exhibit synergistic biological effects that amplify inflammatory cascades and are linked to the pathogenesis of neurological disorders such as epilepsy87,90–92. Consequently, future research should prioritize investigating how PRV infection exacerbates viral encephalitis via PANoptosis-driven synergistic release of HMGB1 and IL-1β (Supplementary Fig. 8). Previous studies demonstrated that PRV infection promotes IL-1β and IL-18 release via AIM2- and NLRP3-inflammasome-mediated pyroptosis, aggravating inflammatory responses in mice93,94. Similarly, our study found that pretreatment with pyroptosis inhibitor (DMF) alone significantly suppressed HMGB1 and IL-1β release in THP-1 Mφ (Fig. 6C, D) and C57BL/6J mice (Fig. 6G, H). However, combinatorial drug therapy targeting pyroptosis, apoptosis, and necroptosis (e.g., DMF + ZVAD + NSA) proved more effective than monotherapy, achieving > 90% inhibition of PRV-induced cell death in vitro (P-values < 0.001) (Figs. 1E and 3C) and significant protection against mortality in vivo (P-values < 0.05) (Fig. 6G). These findings underscore PANoptosis as a therapeutic target for PRV-associated inflammatory disorders. Nevertheless, since there is currently no specific inhibitor of PANoptosis or gene-knockout mice strain available in which PANoptosis is specifically impaired, the inhibition of inflammatory cytokines and virus replication in vivo warrant further investigation. Although our data show that suppression of PANoptotic signaling markedly improves survival and is accompanied by lower cPRV titers in the brain, it is plausible that mortality is principally driven by a PANoptosis-dependent cytokine storm rather than by directly affecting viral burden. Several mechanisms could explain the observed decrease in viral titer following PANoptosis inhibition. First, given that components of PANoptosis (notably pyroptosis and necroptosis) are lytic, their inhibition may reduce extracellular release of progeny virions and limit local virus spread. Second, reduced PANoptosis and DAMP release may protect endothelial cells and tight junctions, limiting blood–brain barrier disruption and subsequent viral dissemination into the CNS. Finally, tempering excessive DAMP/cytokine signaling could prevent immune exhaustion or dysdirected inflammation, allowing a more coordinated antiviral response. Dissecting these possibilities will require experiments that directly compare intracellular versus extracellular virus production, quantify immune-cell survival and function, and assess barrier integrity and immune cell recruitment in the presence or absence of PANoptotic signaling. In conclusion, PRV infection was found to trigger PANoptosis both in vitro and in vivo. Mechanistically, we identified that innate sensor proteins AIM2, Pyrin, and ZBP1 participate in the assembly of the PANoptosome within the PRV-infected THP-1 Mφ. Upregulated IRF1 acted as a key transcription factor to promote gene expression of the innate sensor proteins ZBP1 and AIM2, which enhanced the activation of the PANoptotic signaling pathway during PRV infection. From a pathological perspective, the critical role of PANoptosis in the pathogenesis of PRV was highlighted. Our findings revealed that PRV exacerbates host inflammatory responses by provoking the excessive release of pro-inflammatory mediators HMGB1 and IL-1β, which was driven by PANoptosis. Notably, we discovered that combinatorial drug therapy (pyroptosis inhibitor Dimethyl Fumarate, apoptosis inhibitor Z-VAD-FMK, and necroptosis inhibitor Necrosulfonamide) administered prior to PRV infection significantly attenuated PRV-induced extracellular release of pro-inflammatory mediators HMGB1 and IL-1β in vitro, markedly reduced levels of HMGB1 and IL-1β in cerebral tissue of PRV-infected mice, and effectively conferred significant protection against PRV challenge in vivo. Our studies provide compelling evidence that PRV infection triggers PANoptosis, elucidate the mechanism by which PRV infection triggers PANoptosis, and underscore the significant role of PANoptosis in the enhanced inflammatory responses induced by PRV infection. Materials and methods Ethics statement Animal experiments performed in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of Yangzhou University (Approval Number: 202206009). All experimental procedures were executed in strict compliance with the ARRIVE guidelines 2.095. Animal care followed the National Research Council’s Guide for the Care and Use of Laboratory Animals (Eighth Edition, 2011). Euthanasia procedures adhered to the American Veterinary Medical Association (AVMA) Guidelines (2020 Edition). We have complied with all relevant ethical regulations for animal use. Cell culture THP-1 cells (RRID: CVCL_0006), a human leukemia monocytic cell line, were kindly provided by Professor Sujuan Chen (College of Veterinary Medicine, Yangzhou University). THP-1-derived macrophages (THP-1 Mφ) were differentiated from monocytic THP-1 cells through a three-day stimulation with phorbol 12-myristate 13-acetate (PMA)9,38. THP-1 cells are a well-established, widely used model for studying macrophage-mediated inflammatory signaling and PANoptosis, offering a reproducible and tractable system for mechanistic dissection. PK-15 cells (RRID: CVCL_2160), a porcine renal epithelial cell line, were purchased from the American Type Culture Collection (ATCC, CCL-33). C8-D1A cells (RRID: CVCL_6379), a murine cerebellar astroglial cell line, were purchased from the ATCC (CRL-2541). HEK-293T cells (RRID: CVCL_0063), a human embryonic kidney epithelial-like cell line, were purchased from the ATCC (CRL-3216). WSL-R cells (RRID: CVCL_0166), a wild board lung-derived immortalized cell line, were kindly provided by Professor Jun Han (College of Veterinary Medicine, China Agricultural University). Vero cells (RRID: CVCL_0059), an African green monkey kidney cell line, were kindly provided by Professor Jianzhong Zhu (College of Veterinary Medicine, Yangzhou University). Bone marrow-derived macrophages (BMDMs) were differentiated from murine primary bone marrow cells through a one week stimulation with murine colony-stimulating factor (M-CSF)70. The preparation of BMDMs was performed strictly in accordance with established “STAR Protocols” 70. THP-1 and WSL-R cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Gibco, C11875500BT), while HEK-293T, PK-15, C8-D1A, and BMDM cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (HyClone, SH30604.01). Cells used in this study were all cultured in a medium supplemented with 10% fetal bovine serum (FBS) (LONSERA, U512-001) and 1% penicillin/streptomycin (Solarbio, P1400) at 37 °C in 5% CO2. The cell lines were authenticated using Short Tandem Repeat (STR) profiling. All cells were tested for mycoplasma contamination using mycoplasma detection PCR and were found to be negative for mycoplasma contamination. The experimental designs in vitro were outlined in Supplementary Fig. 9. Viruses One PRV classical strain, designated JS-2020 (hereafter abbreviated as “cPRV”), was isolated from PR-suspected aborted swine96. Based on the PRV variant strain HN1201, a recombinant PRV (hereafter abbreviated as “vPRV”) expressing the GFP reporter gene was constructed by homologous recombination97. Viruses used in this study were preserved in our laboratory. Viral titers were quantified as the 50% tissue culture infectious dose (TCID50) using the Reed-Muench method in PK-15 cells. Mice Six- to eight-week-old C57BL/6J mice (female, 18–20 g) were purchased from Institute of Comparative Medicine, Yangzhou University [production license number: SCXK (Su) 2022-0009]. Mice were bred in the specific pathogen-free (SPF) grade facility of the Laboratory Animal Center of Yangzhou University [use license number: SYXK (Su) 2022-0044]. Mice were housed in individually ventilated cages and maintained under standard conditions (room temperature: 20–25 °C; relative humidity: 45–65%; 12 h/12 h light/dark cycle; free access to food and water). Mice were acclimatized for at least one week before experiments. Mice experiments For establishing a PRV infection model in mice, six C57BL/6J mice (6–8 weeks, female, 18–20 g) were randomly divided into two groups (challenge group and control group), with three mice per group. All mice were acclimated for one week prior to the formal experiment. Each mouse in the challenge group received an intraperitoneal injection of 1 × 103 TCID50 of cPRV, while mice in the control group were injected intraperitoneally with an equivalent volume of PBS. Clinical manifestations of the mice were subsequently monitored. Mice exhibiting “intense pruritus and neurological symptoms” were subjected to increased monitoring frequency. Once a moribund state was observed, priority was given to orbital blood collection (to separate serum), followed by euthanasia. Complete brain, lung, spleen, liver, and kidney tissues were then dissected. Half of the tissue samples were fixed in 4% paraformaldehyde (for subsequent paraffin embedding and tissue section preparation), while the remaining half (with the hippocampus further isolated from the brain tissue) were stored in an ultra-low temperature freezer for subsequent analyses. All mice were euthanized on day 5 post-challenge, followed by identical tissue collection and processing procedures. For the survival analysis in drug intervention trials in mice, eighty C57BL/6J mice (6–8 weeks old, female, 18–20 g) were randomly divided into five groups (16 mice per group). Each group received intraperitoneal injections of either DMSO, Dimethyl Fumarate (DMF), Z-VAD-FMK (ZVAD), Necrosulfonamide (NSA), or a triple combination of DMF + ZVAD + NSA, with a standardized injection volume of 40 μL per mouse using a 50 μL microliter syringe (Hamilton, Bonaduz, Switzerland) (detailed drug information and preparation protocols shown in Tables 1 and 2)98. After 12 h of pretreatment with the respective drugs, each group was equally subdivided into a challenge subgroup (8 mice) and a control subgroup (8 mice). Mice in the challenge subgroups received an intraperitoneal injection of 1 × 10³ TCID50 of cPRV, while control subgroup mice were injected with an equivalent volume of PBS. The same drug administration regimen was conducted every 24 h for three days. Starting from the challenge, mice were monitored continuously for 14 days, with close observation of clinical manifestations and rigorous documentation of survival rates across all groups. The survival curves were established upon completion of the experiment.Table 1Key information on the three cell death inhibitors used in pharmacological intervention studies in vivoNameSolubilityVehicleStock concentration (mM)Administration dose (mg/kg)Maximum tolerated volume per mouse via single intraperitoneal injection (μL)103DMFlipid-solubleDMSO277.535040ZVADlipid-solubleDMSO220.531040NSAlipid-solubleDMSO60.682040Dimethyl Fumarate was abbreviated as DMF, Z-VAD-FMK was abbreviated as ZVAD, and Necrosulfonamide was abbreviated as NSA. [ ] represents the relevant reference.Table 2Drugs preparation protocols for individual mice in each group during pharmacological intervention experiments in vivoGroupTreatmentComponentDrugs preparation protocols per mousePRVVehicle controlDMSODMSO (40 μL)SingleDD (22.5 μL) + DMSO (17.5 μL)SingleZZ (1.8 μL) + DMSO (38.2 μL)SingleNN (12.8 μL) + DMSO (27.2 μL)TripleD + Z + ND (22.5 μL) + Z (1.8 μL) + N (12.8 μL) + DMSO (2.9 μL)PBSVehicle controlDMSODMSO (40 μL)SingleDD (22.5 μL) + DMSO (17.5 μL)SingleZZ (1.8 μL) + DMSO (38.2 μL)SingleNN (12.8 μL) + DMSO (27.2 μL)TripleD + Z + ND (22.5 μL) + Z (1.8 μL) + N (12.8 μL) + DMSO (2.9 μL)Dimethyl Fumarate was abbreviated as D, Z-VAD-FMK was abbreviated as Z, and Necrosulfonamide was abbreviated as N. Dosage was calculated based on an average body weight of 18 g per mouse. Table 1Key information on the three cell death inhibitors used in pharmacological intervention studies in vivoNameSolubilityVehicleStock concentration (mM)Administration dose (mg/kg)Maximum tolerated volume per mouse via single intraperitoneal injection (μL)103DMFlipid-solubleDMSO277.535040ZVADlipid-solubleDMSO220.531040NSAlipid-solubleDMSO60.682040Dimethyl Fumarate was abbreviated as DMF, Z-VAD-FMK was abbreviated as ZVAD, and Necrosulfonamide was abbreviated as NSA. [ ] represents the relevant reference. Key information on the three cell death inhibitors used in pharmacological intervention studies in vivo Dimethyl Fumarate was abbreviated as DMF, Z-VAD-FMK was abbreviated as ZVAD, and Necrosulfonamide was abbreviated as NSA. [ ] represents the relevant reference. Table 2Drugs preparation protocols for individual mice in each group during pharmacological intervention experiments in vivoGroupTreatmentComponentDrugs preparation protocols per mousePRVVehicle controlDMSODMSO (40 μL)SingleDD (22.5 μL) + DMSO (17.5 μL)SingleZZ (1.8 μL) + DMSO (38.2 μL)SingleNN (12.8 μL) + DMSO (27.2 μL)TripleD + Z + ND (22.5 μL) + Z (1.8 μL) + N (12.8 μL) + DMSO (2.9 μL)PBSVehicle controlDMSODMSO (40 μL)SingleDD (22.5 μL) + DMSO (17.5 μL)SingleZZ (1.8 μL) + DMSO (38.2 μL)SingleNN (12.8 μL) + DMSO (27.2 μL)TripleD + Z + ND (22.5 μL) + Z (1.8 μL) + N (12.8 μL) + DMSO (2.9 μL)Dimethyl Fumarate was abbreviated as D, Z-VAD-FMK was abbreviated as Z, and Necrosulfonamide was abbreviated as N. Dosage was calculated based on an average body weight of 18 g per mouse. Drugs preparation protocols for individual mice in each group during pharmacological intervention experiments in vivo Dimethyl Fumarate was abbreviated as D, Z-VAD-FMK was abbreviated as Z, and Necrosulfonamide was abbreviated as N. Dosage was calculated based on an average body weight of 18 g per mouse. For the ELISA analysis in drug intervention trials in mice, eighty C57BL/6J mice (6–8 weeks old, female, 18–20 g) were randomly divided into five groups (16 mice per group) (Supplementary Fig. 7G). Each group received intraperitoneal injections of either DMSO, Dimethyl Fumarate (DMF), Z-VAD-FMK (ZVAD), Necrosulfonamide (NSA), or a triple combination of DMF + ZVAD + NSA, with a standardized injection volume of 40 μL per mouse using a 50 μL microliter syringe (Hamilton, Bonaduz, Switzerland) (detailed drug information and preparation protocols shown in Tables 1 and 2)98. After 12 h of pretreatment with the respective drugs, each group was further subdivided into a challenge subgroup (8 mice) and a control subgroup (8 mice). Mice in the challenge subgroups received an intraperitoneal injection of 1 × 10³ TCID50 of cPRV, while control subgroup mice were injected with an equivalent volume of PBS. The same drug administration protocol was conducted every 24 h for three days. All mice were euthanized on day 5 post-challenge (48 h after the final drug administration), and complete brain tissue samples were dissected and stored in an ultra-low temperature freezer for subsequent analyses. Chemical reagents Z-VAD-FMK (HY-16658B), Dimethyl Fumarate (HY-17363), Necrosulfonamide (HY-100573), and Phorbol 12-myristate 13-acetate (PMA, HY18739) were purchased from MedChemExpress (New Jersey, USA). Animal-free Recombinant Murine M-CSF (AF-315-02) was purchased from PeproTech (New Jersey, USA). Universal 4% paraformaldehyde fix solution (G1101) was purchased from Servicebio (Wuhan, China). RIPA lysis buffer (P0013B), NP-40 lysis buffer (P0013F), IP lysis buffer (P0013J), protease and phosphatase inhibitor cocktail (P1048), nuclear and cytoplasmic protein extraction kit (P0028) were purchased from Beyotime (Shanghai, China). Bicinchoninic acid (BCA) protein assay kit (PA115), universal DNA purification kit (DP214), TRIzol Universal (DP424) were purchased from TIANGEN (Beijing, China). Non-fat powdered milk (A600669) was purchased from Sangon Biotech (Shanghai, China). Bovine serum albumin (BSA) (A8020), Tween-20 (T8220) were purchased from Solarbio (Beijing, China). SuperSignalTM enhanced chemiluminescence substrate (A38556), PierceTM Crosslink Magnetic IP/Co-IP Kit (88805), PierceTM streptavidin magnetic beads (88817), LipofectamineTM 3000 (L3000015) were purchased from Thermo Fisher Scientific (Massachusetts, USA). Dual luciferase reporter assay kit (DL101-01) and CCK-8 cell counting kit (A311) were purchased from Vazyme (Nanking, China). Antibodies Anti-total and cleaved GSDMD (ab255603, for mouse, 1:1000), anti-ASC (ab309497, 1:1000), anti-phospho-MLKL (S345, 1:1000) (ab196436, for mouse), anti-phospho-MLKL (S358) (ab187091, for human and pig, 1:1000), anti-Histone H3 (ab1791, 1:1000) primary antibodies were purchased from Abcam (Cambridge, UK). Anti-IL-1β (sc-12742, 1:500), anti-HMGB1 (sc-56698, 1:500), anti-GSDMD (sc-81868, for pig, 1:500), anti-AIM2 (sc-515642, 1:500), anti-Pyrin (sc-390938, 1:500), anti-ZBP1 (sc-271483, 1:500), anti-total MLKL (sc-293201 for human and pig, 1:500) primary antibodies and Alexa Fluor 488-conjugated anti-ASC (sc-514414 AF488, 1:50), Alexa Fluor 546-conjugated anti-AIM2 (sc-515514 AF546, 1:50), Alexa Fluor 594-conjugated anti-Pyrin (sc-390938 AF594, 1:50), Alexa Fluor 647-conjugated anti-ZBP1 (sc-271483 AF647, 1:50), Alexa Fluor 594-conjugated anti-RIPK3 (sc-374639 AF594, 1:50), Alexa Fluor 546-conjugated anti-caspase-8 (sc-5263 AF546, 1:50) were purchased from Santa Cruz (California, USA). Anti-IRF1 (T55507, 1:1000), Anti-pro-caspase-3 p12 (T55783, for mouse, 1:1000), anti-pro-caspase-3 p12 (T40044, for human and pig, 1:1000), anti-GSDMD (P30823, for pig, 1:1000), anti-total MLKL (TD7412, for mouse, 1:1000) primary antibodies were purchased from Abmart (Shanghai, China). Anti-total and cleaved GSDMD (GTX135366, for human, 1:1000) were purchased from GeneTex (California, USA). Anti-GAPDH (10494-1-AP, 1:2000) primary antibody was purchased from Proteintech (Hubei, China). The anti-PRV-gB mouse monoclonal antibody (1:1000) was preserved in our laboratory99. Rabbit control IgG (AC005) was purchased from ABclonal (Hubei, China). Anti-mouse IgG for IP HRP (RA1009-01) was purchased from Vazyme (Jiangsu, China). Anti-mouse IgG (H + L), F(ab′)2 Fragment (Alexa Fluor® 647 Conjugate, #4410, 1:2000), Anti-mouse IgG (H + L), F(ab′)2 Fragment (Alexa Fluor® 488 Conjugate, #4408, 1:2000), Anti-rabbit IgG (H + L), F(ab′)2 Fragment (Alexa Fluor® 555 Conjugate, #4413, 1:2000) secondary antibodies were purchased from Cell Signaling Technology. Peroxidase AffiniPure® Goat Anti-Rabbit IgG (H + L) (111-035-003, 1:5000) and Peroxidase AffiniPure® Goat Anti-Mouse IgG (H + L) (115-035-003, 1:5000) were purchased from Jackson ImmunoResearch. Plasmids The second-generation lentiviral packaging plasmids psPAX2 (#12260), lentiviral envelope plasmid pMD.2 G (#12259), and lentiviral vector pLKO.1-TRC (#10878) for stable gene knockdown were purchased from Addgene (Massachusetts, USA). Dual-luciferase reporter plasmids pRL-TK (E2241), vector pGL3-Basic (E1751) were purchased from Promega (Wisconsin, USA). Eukaryotic expression vector pcDNATM 3.1(+) (V790-20) was purchased from Thermo Fisher Scientific (Massachusetts, USA). Lentiviral vector pCN179-puro-GFP for stable gene expression was preserved in our laboratory. The promoters of AIM2, MEFV, and ZBP1 were amplified by PCR and cloned into the vector pGL3-Basic, respectively (primers shown in Table 3). The complete coding sequence (CDS) of human IRF1 (NCBI accession: NM_002198.3) was amplified by PCR and cloned into vector pCN179-puro-GFP and pcDNA3.1(+) (primers shown in Table 4). The shRNA of IRF1 was synthesized in Sangon Biotech (Shanghai, China) and cloned into the vector PLKO.1-TRC (primers shown in Table 5). The plasmid pcDNA3.1-IRF7 was kindly provided by Prof. Jianzhong Zhu (College of Veterinary Medicine, Yangzhou University).Table 3The primer pairs used to amplify the promoter sequences of AIM2, MEFV, and ZBP1 to be inserted during the construction of the luciferase reporter plasmidsPrimersSequence (5′-3′)pGL3-Basic-AIM2-promoter-FcgatctaagtaagctATTTGTCCAAACCCACAGAATGTpGL3-Basic-AIM2-promoter-RccggaatgccaagctCAGCTCCTCTATGGTGCTTACCTpGL3-Basic-ZBP1-promoter-FcgatctaagtaagctCAGAGAGGTAGCGCCACACApGL3-Basic-ZBP1-promoter-RccggaatgccaagctTGCTGACAGCAGCTGCAApGL3-Basic-MEFV-promoter-FcgatctaagtaagctATTTCCCAGGAGTAATAGCCGAGpGL3-Basic-MEFV-promoter-RccggaatgccaagctTGGTGCTGAGCAGGAGAGGThe underlined portion represents the 15-base homology arms at both ends of the linearized pGL3-Basic vector.Table 4The primer pair used to amplify the IRF1-CDS sequence to be inserted during the construction of the IRF1 eukaryotic expression plasmidPrimersSequence (5′-3′)pcDNA3.1-IRF1-CDS-FgtttaaacttaagctATGCCCATCACTCGGATGCGpcDNA3.1-IRF1-CDS-RgctcggtaccaagctCTACGGTGCACAGGGAATGGThe underlined portion represents the 15-base homology arms at both ends of the linearized pcDNA3.1 vector.Table 5The primer pairs used to obtain the functional fragments for knockdown (shRNA) and overexpression (CDS) of IRF1 gene to be inserted during the construction of lentiviral expression plasmidsPrimersSequence (5′-3′)pLKO.1-IRF1-shRNA-B2-FCCGGGCGTGTCTTCACAGATCTGAACTCGAGTTCAGATCTGTGAAGACACGCTTTTTGpLKO.1-IRF1-shRNA-B2-RAATTCAAAAAGCGTGTCTTCACAGATCTGAACTCGAGTTCAGATCTGTGAAGACACGCpLKO.1-shRNA-Scrambled-FCCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTGpLKO.1-shRNA-Scrambled-RAATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGpCN179-IRF1-CDS-FagatccgctagtcccATGCCCATCACTCGGATGCGpCN179-IRF1-CDS-RgcggatccaaatcccCTACGGTGCACAGGGAATGGThe text highlighted in blue represents the sticky end bases formed by enzymatic digestion at both ends of the linearized pLKO.1-TRC vector; the red-highlighted text represents the 21-base sense strand sequence of the shRNA; the green-highlighted text represents the 21-base reverse complementary strand sequence of the shRNA. The underlined portion represents the 15-base homology arms at both ends of the linearized pCN179-puro-GFP vector. Table 3The primer pairs used to amplify the promoter sequences of AIM2, MEFV, and ZBP1 to be inserted during the construction of the luciferase reporter plasmidsPrimersSequence (5′-3′)pGL3-Basic-AIM2-promoter-FcgatctaagtaagctATTTGTCCAAACCCACAGAATGTpGL3-Basic-AIM2-promoter-RccggaatgccaagctCAGCTCCTCTATGGTGCTTACCTpGL3-Basic-ZBP1-promoter-FcgatctaagtaagctCAGAGAGGTAGCGCCACACApGL3-Basic-ZBP1-promoter-RccggaatgccaagctTGCTGACAGCAGCTGCAApGL3-Basic-MEFV-promoter-FcgatctaagtaagctATTTCCCAGGAGTAATAGCCGAGpGL3-Basic-MEFV-promoter-RccggaatgccaagctTGGTGCTGAGCAGGAGAGGThe underlined portion represents the 15-base homology arms at both ends of the linearized pGL3-Basic vector. The primer pairs used to amplify the promoter sequences of AIM2, MEFV, and ZBP1 to be inserted during the construction of the luciferase reporter plasmids The underlined portion represents the 15-base homology arms at both ends of the linearized pGL3-Basic vector. Table 4The primer pair used to amplify the IRF1-CDS sequence to be inserted during the construction of the IRF1 eukaryotic expression plasmidPrimersSequence (5′-3′)pcDNA3.1-IRF1-CDS-FgtttaaacttaagctATGCCCATCACTCGGATGCGpcDNA3.1-IRF1-CDS-RgctcggtaccaagctCTACGGTGCACAGGGAATGGThe underlined portion represents the 15-base homology arms at both ends of the linearized pcDNA3.1 vector. The primer pair used to amplify the IRF1-CDS sequence to be inserted during the construction of the IRF1 eukaryotic expression plasmid The underlined portion represents the 15-base homology arms at both ends of the linearized pcDNA3.1 vector. Table 5The primer pairs used to obtain the functional fragments for knockdown (shRNA) and overexpression (CDS) of IRF1 gene to be inserted during the construction of lentiviral expression plasmidsPrimersSequence (5′-3′)pLKO.1-IRF1-shRNA-B2-FCCGGGCGTGTCTTCACAGATCTGAACTCGAGTTCAGATCTGTGAAGACACGCTTTTTGpLKO.1-IRF1-shRNA-B2-RAATTCAAAAAGCGTGTCTTCACAGATCTGAACTCGAGTTCAGATCTGTGAAGACACGCpLKO.1-shRNA-Scrambled-FCCGGCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTGpLKO.1-shRNA-Scrambled-RAATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGpCN179-IRF1-CDS-FagatccgctagtcccATGCCCATCACTCGGATGCGpCN179-IRF1-CDS-RgcggatccaaatcccCTACGGTGCACAGGGAATGGThe text highlighted in blue represents the sticky end bases formed by enzymatic digestion at both ends of the linearized pLKO.1-TRC vector; the red-highlighted text represents the 21-base sense strand sequence of the shRNA; the green-highlighted text represents the 21-base reverse complementary strand sequence of the shRNA. The underlined portion represents the 15-base homology arms at both ends of the linearized pCN179-puro-GFP vector. The primer pairs used to obtain the functional fragments for knockdown (shRNA) and overexpression (CDS) of IRF1 gene to be inserted during the construction of lentiviral expression plasmids CCGGGCGTGTCTTCACAGATCTGAACTCGAG TTCAGATCTGTGAAGACACGCTTTTTG AATTCAAAAAGCGTGTCTTCACAGATCTGAA CTCGAGTTCAGATCTGTGAAGACACGC CCGGCCTAAGGTTAAGTCGCCCTCGCTCGAG CGAGGGCGACTTAACCTTAGGTTTTTG AATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAG CGAGGGCGACTTAACCTTAGG The text highlighted in blue represents the sticky end bases formed by enzymatic digestion at both ends of the linearized pLKO.1-TRC vector; the red-highlighted text represents the 21-base sense strand sequence of the shRNA; the green-highlighted text represents the 21-base reverse complementary strand sequence of the shRNA. The underlined portion represents the 15-base homology arms at both ends of the linearized pCN179-puro-GFP vector. Viral inactivation by irradiation rays To inactivate the cPRV, the virus stock of 5 MOI was diluted in 5 mL DMEM within quartz glass petri dishes (100 × 21 mm, Aoxin Quartz Technology) and irradiated by the UV-C source according to a method described previously100,101. The efficiency of UV inactivation was evaluated by the cytopathic effect and immunofluorescence following infection of the irradiated virus onto the PK-15 cells, our data showed that a 30-min UV-C irradiation achieved complete inactivation of cPRV (Supplementary Fig. 1N, O). Quantitative polymerase chain reaction Quantitative polymerase chain reaction (qPCR) based on SYBR Green and TaqMan probe represent two widely adopted approaches for relative and absolute quantification, respectively. For the relative quantification, high-quality total RNA was isolated from THP-1 Mφ at different experimental conditions using TRIzol. Assess the purity of RNA via a bioanalyzer (BioTek Epoch, Vermont, USA), ensuring an A260/A280 ratio of 2.0–2.2. Convert 1 μg of RNA into cDNA with oligo(dT) or random hexamer primers provided in the Hiscript III RT SuperMix for qPCR (+gDNA wiper) kit (R323, Vazyme). Design primers for target genes (e.g., IRF1, AIM2, MEFV, and ZBP1) and reference genes (e.g., β-actin) using Primer Premier (version 5.0, USA), ensuring amplicon lengths of 80–200 bp, melting temperatures (Tm) of 58–62 °C, and minimal primer-dimer formation (primers shown in Table 6). Prepare 20 μL reactions in triplicate using 10 μL of 2 × SYBR qPCR Master Mix (Q711, Vazyme), 0.4 μL of 10 μM forward and reverse primers, 8.2 μL of RNase-free water, and 1 μL of cDNA template. Run reactions on a real-time PCR instrument (ABI QuantStudio 3, California, USA) under the following conditions: initial denaturation at 95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s and 60 °C for 30 s, concluding with a melt curve analysis (95 °C for 15 s, 60 °C for 1 min, and 95 °C for 15 s). For data analysis, calculate the ΔCt value (Ct_target–Ct_reference) for each sample. Normalize ΔCt values of experimental groups to the untreated control group to determine ΔΔCt. Express relative quantification using the formula 2(−ΔΔCt).Table 6The sequences of primers in relative quantitative PCR analysisPrimersSequence (5′-3′)qPCR-human IRF1-FGAGGAGGTGAAAGACCAGAGCAqPCR-human IRF1-RTAGCATCTCGGCTGGACTTCGAqPCR-human AIM2-FGCTGCACCAAAAGTCTCTCCTCqPCR-human AIM2-RCTGCTTGCCTTCTTGGGTCTCAqPCR-human MEFV-FGCTGCTCTTCTGTGAGGATCACqPCR-human MEFV-RCTCAGCTTCTTCAGATGCTCCAGqPCR-human ZBP1-FTGGTCATCGCCCAAGCACTGqPCR-human ZBP1-RGGCGGTAAATCGTCCATGCTqPCR-human β-actin-FCACCATTGGCAATGAGCGGTTCqPCR-human β-actin-RAGGTCTTTGCGGATGTCCACGT Table 6The sequences of primers in relative quantitative PCR analysisPrimersSequence (5′-3′)qPCR-human IRF1-FGAGGAGGTGAAAGACCAGAGCAqPCR-human IRF1-RTAGCATCTCGGCTGGACTTCGAqPCR-human AIM2-FGCTGCACCAAAAGTCTCTCCTCqPCR-human AIM2-RCTGCTTGCCTTCTTGGGTCTCAqPCR-human MEFV-FGCTGCTCTTCTGTGAGGATCACqPCR-human MEFV-RCTCAGCTTCTTCAGATGCTCCAGqPCR-human ZBP1-FTGGTCATCGCCCAAGCACTGqPCR-human ZBP1-RGGCGGTAAATCGTCCATGCTqPCR-human β-actin-FCACCATTGGCAATGAGCGGTTCqPCR-human β-actin-RAGGTCTTTGCGGATGTCCACGT The sequences of primers in relative quantitative PCR analysis For the absolute quantification, high-quality total DNA was extracted from tissues of PRV-infected C57BL/6J mice using a HiPure Tissue DNA Mini kit (D3121, Magen, Shanghai, China). Quantify DNA using a spectrophotometer (BioTek Epoch, Vermont, USA), prioritizing samples with A260/A280 ratios of 1.8–2.0 (DNA). Design TaqMan probes and primers using the software Beacon Designer (version 8.14, California, USA). Probes should be 18–30 nucleotides long, labeled with a 5′ reporter dye (e.g., FAM) and a 3′ quencher (e.g., BHQ1), and positioned between forward and reverse primers to ensure specific hybridization. Amplicons should be 60–150 bp to maximize efficiency (primers and probe shown in Table 7). Prepare a standard curve using serial tenfold dilutions of the plasmid DNA (pMD18T-PRV gD) with known copy numbers (1 × 108 copies/μL). Assemble 20 μL reactions in triplicate using 10 μL of 2 × Premix Taq (R004, TAKARA), 0.5 μL of 10 μM forward and reverse primers, 0.2 μL probe, and 1 μL of DNA template. Load plates into a real-time PCR instrument (ABI QuantStudio 3, California, USA) and run under optimized cycling conditions: initial denaturation at 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s. Generate a standard curve by plotting Ct values against the log10 of the standard’s known copy numbers. Validate the curve with a linear regression slope of −3.1 to −3.6 (90–110% efficiency) and an R² > 0.98. Calculate absolute copy numbers in unknowns by interpolating sample Ct values onto the standard curve.Table 7The sequences of primers and TaqMan probe in absolute quantitative PCR analysisPrimers and TaqMan probeSequence (5′-3′)PRV gD-FGTGGGCGTGTGCGTCTACAPRV gD-RGACCGGGCTGCGCTTTTAPRV gD-ProbeFAM-CGAAGGGGTATCGCCTCCT-BHQ1The symbol “_” indicates fluorophore modification in the probe, and “﹏” represents quencher modification in the probe. Table 7The sequences of primers and TaqMan probe in absolute quantitative PCR analysisPrimers and TaqMan probeSequence (5′-3′)PRV gD-FGTGGGCGTGTGCGTCTACAPRV gD-RGACCGGGCTGCGCTTTTAPRV gD-ProbeFAM-CGAAGGGGTATCGCCTCCT-BHQ1The symbol “_” indicates fluorophore modification in the probe, and “﹏” represents quencher modification in the probe. The sequences of primers and TaqMan probe in absolute quantitative PCR analysis The symbol “_” indicates fluorophore modification in the probe, and “﹏” represents quencher modification in the probe. Dual-luciferase reporter assay pGL3-Basic-AIM2 or pGL3-Basic-MEFV or pGL3-Basic-ZBP1 co-transfected with pcDNA3.1-IRF1 and pRL-TK (to normalize luciferase activity) into the HEK-293T cells. After 24 h post-transfection, the cells were lysed with luciferase lysis buffer. The activity of firefly luciferase and Renilla luciferase was measured, respectively, using the dual luciferase reporter assay kit (Vazyme DL101-01, Nanking, China). Luminescent signals of firefly luciferase and Renilla luciferase were quantified using a microplate reader (Tecan Infinite 200 PRO, Männedorf, Switzerland) equipped with luminescence detection modules. Lentiviral-mediated IRF1 knockdown and overexpression in THP-1 For lentivirus production, HEK-293T cells cultured in the 10 cm dish were co-transfected with 10 µg of pLKO.1-TRC-IRF1 or pCN179-puro-GFP-IRF1, 7.5 µg psPAX2, and 2.5 µg pMD.2 G using Lipofectamine 3000. Viral supernatants were harvested at 48- and 72-h post-transfection, filtered through 0.45 µm PVDF membranes, and concentrated by ultrafiltration. For transduction, THP-1 were infected with lentivirus at an MOI of 10 in the presence of 8 µg/mL polybrene. To enhance transduction efficiency, plates were centrifuged at 800 × g for 90 min at 32 °C (spinoculation) followed by 6-h incubation at 37 °C. Stable cell lines were selected with 2 μg/mL puromycin for 10 days, with media refreshed every 48 h. The efficiency of gene knockdown and overexpression was systematically validated through parallel quantification of IRF1 mRNA and protein levels (Supplementary Fig. 5E–G). Western blotting analysis Protein lysates were extracted from cells or tissues using RIPA lysis buffer supplemented with protease and phosphatase inhibitor cocktail. Total protein concentration was quantified via BCA assay. 30–50 μg of protein per sample was separated on 8–12% SDS-polyacrylamide gels (PAGE) under reducing conditions. Proteins were transferred to polyvinylidene fluoride (PVDF) membranes (Pall, BSP0161) using a wet transfer system (Tanon, VE-186), followed by blocking with 5% non-fat milk in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 1 h at room temperature. Membranes were incubated overnight at 4 °C with primary antibodies targeting PANoptotic signaling molecules (e.g., AIM2, IRF1, Caspase-3), pro-inflammatory mediators (e.g., HMGB1 and IL-1β), and loading controls (e.g., GAPDH). After three TBST washes, membranes were probed with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using SuperSignalTM enhanced chemiluminescence substrate and imaged on a Tanon 5200 imaging system. Band intensity quantification was performed using software Fiji, with target protein expression normalized to the loading controls. DNA pull-down The DNA pull-down assay was performed to identify the binding ability of transcription factor IRF1 to the promoter sequences of genes encoding sensor proteins AIM2, MEFV, and ZBP1. Experimental procedures strictly followed the manufacturer’s instructions, and the experimental design referenced published protocols102,103. Briefly, a 2000 bp biotinylated DNA probe containing the promoter sequence of the target gene (e.g., AIM2, MEFV, and ZBP1) was generated by PCR amplification using primers (as shown in Table 8) conjugated with biotin at the 5′ end. THP-1 Mφ were infected with cPRV at an MOI of 5. At 18 hpi, infected THP-1 Mφ were lysed in NP-40 lysis buffer (supplemented with protease and phosphatase inhibitor cocktail) for 30 min on ice. Lysates were precleared with streptavidin-coated magnetic beads for 1 h at 4 °C to reduce non-specific binding. Subsequently, 2 μg of biotinylated promoter probe was incubated with 500 μg of precleared lysate in binding buffer for 2 h at 4 °C with gentle rotation. Streptavidin magnetic beads were then added to capture DNA-protein complexes, followed by an additional one-hour incubation. Beads were washed five times with high-stringency wash buffer to remove unbound proteins. Bound proteins were eluted by boiling in 2 × SDS-PAGE loading buffer at 95 °C for 10 min and analyzed by WB. For specificity controls, parallel experiments were conducted using a scrambled DNA probe of identical length and GC content, as well as lysates from mock-treated cells.Table 8Universal primer pair used for amplifying biotinylated promoter sequences of AIM2, MEFV, and ZBP1 in DNA pull-down assaysPrimersSequence (5′-3′)Promoter Universal Biotin-F5′ Biotin-CTAGCAAAATAGGCTGTCCCPromoter Universal Biotin-R5′ Biotin-CTTTATGTTTTTGGCGTCTTCCAThe 5′-Biotin represents the biotin label attached to the 5′ end of the synthesized primers. Table 8Universal primer pair used for amplifying biotinylated promoter sequences of AIM2, MEFV, and ZBP1 in DNA pull-down assaysPrimersSequence (5′-3′)Promoter Universal Biotin-F5′ Biotin-CTAGCAAAATAGGCTGTCCCPromoter Universal Biotin-R5′ Biotin-CTTTATGTTTTTGGCGTCTTCCAThe 5′-Biotin represents the biotin label attached to the 5′ end of the synthesized primers. Universal primer pair used for amplifying biotinylated promoter sequences of AIM2, MEFV, and ZBP1 in DNA pull-down assays The 5′-Biotin represents the biotin label attached to the 5′ end of the synthesized primers. Confocal microscopy analysis Confocal microscopy analysis was performed using a high-resolution confocal laser scanning confocal system equipped with a 63 × oil immersion objective lens (Zeiss LSM880, Oberkochen, Germany). Adherent cells (e.g., C8-D1A, WSL, and BMDM) were grown on NuncTM Thermanox Coverslips (174950, Thermo Scientific). All the cells were fixed with universal 4% paraformaldehyde fix solution for 15 min at room temperature, permeabilized with 0.1% Triton ×-100 for 10 min, and blocked with 5% BSA in PBS prior to incubation with primary antibodies overnight at 4 °C. Following three washes with PBS containing 0.05% Tween-20, samples were incubated with Alexa Fluor-conjugated secondary antibodies for 1 h at 37 °C, with nuclear counterstaining achieved using DAPI (1 μg/mL) during the final wash cycle. The secondary antibody incubation step could be omitted when directly conjugated primary antibodies are employed. Cell-based statistics on the proportion of PANoptosome (ASC/Caspase-8/RIPK3 Speck+ Cells or ASC/AIM2/ZBP1/Pyrin Speck+ Cells) was quantified by using ImageJ and analyzed by using the software GraphPad Prism (version 10.1.2, California, USA). Enzyme-linked immunosorbent assay (ELISA) Human precursor interleukin 1 beta (pro-IL-1β) ELISA kit (ml058228) was purchased from Enzyme-linked Biotechnology (Shanghai, China). ElaBoXTM human HMGB1 ELISA kit (SEKH-0409) and ElaBoXTM human IL-1β ELISA kit (SEKH-0002) were purchased from Solarbio (Beijing, China). Mouse IL-1β ELISA kit (AB-B8544) and Mouse HMGB1 ELISA kit (AB-B619111) were purchased from Abmart (Shanghai, China). The level of pro-inflammatory mediators in cell culture supernatant, serum, and tissues were determined strictly according to the manufacturer’s protocol. Optical density (OD) values of detected samples were determined via dual-wavelength detection using a microplate spectrophotometer (BioTek Epoch, Vermont, USA), with measurements acquired at the primary absorption wavelength of 450 nm and a reference wavelength of 630 nm to correct for nonspecific background interference. Histological analysis The brain tissue of PRV-infected mice was fixed overnight in the universal 4% paraformaldehyde fix solution. Histological analysis of brain tissue damage was performed using standard H&E staining. Histological analysis of viral antigen distribution in the brain tissue was performed using standard IHC staining. All the results were observed and analyzed using an inverted optical microscope (OLYMPUS IXplore Standard, Tokyo, Japan). Statistics and reproducibility For quantitative assays (e.g., RT-qPCR), all experiments were performed using three independent biological replicates (n = 3). Furthermore, each biological sample was analyzed in technical triplicates to ensure measurement accuracy. The data were analyzed statistically by the software GraphPad Prism (version 10.1.2, California, USA). All data were expressed as mean ± standard error of the mean (SEM) of three independent experiments (n = 3). Statistical analysis was performed using unpaired, two-tailed Student’s t-test for two-group comparisons and log-rank test for survival experiments. P-values < 0.05 were considered to be statistically significant. *, P-values < 0.05; **, 0.001 < P-values < 0.01; ***, P-values < 0.001; ns, P-values > 0.05 was considered statistically non-significant. For all representative images, experiments were independently repeated at least three times with similar results. Supplementary information Supplementary Figs. Supplementary Data 1 for Statistical Chart Supplementary Figs. Supplementary Data 1 for Statistical Chart